跳至主要内容
临床试验/NL-OMON52079
NL-OMON52079尚未招募4 期

The effect of extra hydration on kidney function during carboplatin-pemetrexed-pembrolizumab in patients with advanced non-small cell lung cancer.;*Hydration to prevent nephrotoxicity due to pemetrexed (HydraPem Study)* - HydraPem Study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 118 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
118

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Age > 18 years
  • Patients must be willing and capable of giving written informed consent
  • Patients with advanced non-squamous cell lung cancer, receiving first line
  • treatment with pemetrexed/pembrolizumab maintenance after
  • carboplatin/pemetrexed/pembrolizumab.
  • Adequate hematological, renal and liver functions.

排除标准

  • Subject with an active auto-immune disease requiring systemic treatment
  • Lung disease requiring systemic steroids in doses of >10 mg prednisolone (or
  • equivalent dose of another steroid)
  • Previous allogeneic or organ transplant
  • Known heart failure
  • Myocardial infarction previous 6 months
  • Serious concomitant systemic disorders (for example active infection,
  • unstable cardiovascular disease) which in the opinion of the investigator would
  • compromise the patient's ability to complete the study, or would interfere with
  • the evaluation of the efficacy and safety of the study treatment

研究者

相似试验

The effect of extra hydration on kidney function... | 临床试验